No­vo in­fus­es cash in­to 4 biotechs, adding to their ar­se­nal for the su­per­bugs bat­tle to come

A year af­ter No­vo Hold­ings launched a $165 mil­lion fund to fill what it sees as an ear­ly-stage fund­ing gap in re­search ad­dress­ing the grow­ing threat of an­timi­cro­bial re­sis­tance, it’s of­fer­ing a re­view of four in­vest­ments No­vo has made to­tal­ing $20 mil­lion.

As­traZeneca-backed En­ta­sis Ther­a­peu­tics, Lund Uni­ver­si­ty spin­out Min­er­vax and UK-based Pro­car­ta Biosys­tems were se­lect­ed along­side Polyphor, a Swiss biotech that pre­vi­ous­ly an­nounced No­vo’s back­ing of its out­er mem­brane pro­tein tar­get­ing an­tibi­otics (OMP­TA) pro­grams.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.